Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial (Q84342991)

From Wikidata

Jump to navigation Jump to search

scientific article published on 09 June 2012

Language	Label	Description	Also known as
English	Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial	scientific article published on 09 June 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

0 references

type 2 diabetes

0 references

Francesco Dotta

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Baptist Gallwitz

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Juan Guzman

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Bruno Guerci

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Rafael Simó

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Bruce R Basson

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Andreas Festa

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Jacek Kiljański

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Hélène Sapin

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Michael Trautmann

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Guntram Schernthaner

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

language of work or name

0 references

publication date

9 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

379

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

9833

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

2270-2278

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of type 2 diabetes: new and future developments in treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Preservation of β-cell function: the key to diabetes prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of glucagon-like peptide-1 on the beta cell

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide versus glibenclamide in patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(12)60479-6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84342991&oldid=1425534940"